KCNN4 and neoplasm: Inhibition of KCa3.1 channels has been shown to reduce tumor proliferation and enhance chemosensitivity in preclinical models (Liu et al. 2015; Chen et al. 2023), and our pathway analysis suggests that disrupting potassium‐dependent signalling cascades, such as Wnt/β‐catenin and MAPK signalling, may further potentiate therapeutic efficacy.